£400

SMi is delighted to announce the 13th annual ADMET conference returning to London on the 9th - 10th July 2018, featuring two half-day post-conference workshop on the 11th July!

Developments in ADMET and novel technologies determine the properties of a drug candidate in the preclinical stage of drug discovery. Poor ADMET properties are the principal cause for a candidate to fail at any stage of drug development. ADME-Toxicology and Pharmacokinetic studies are the key strategic check-points for pharmaceutical companies to reduce drug discovery cost, and minimise production times.

The growing use of ADMET technologies is driving the market growth, which is estimated to reach $14,319.9 Million by 2022, with a CAGR of 10.6% from 2016 to 2022*. The main objective of early prediction of ADME properties of a compound is to increase the success rate of it reaching the development stage.

*Source: http://bit.ly/2hMJcgU

Join our expert speaker panel at the 13th annual ADMET conference to ensure you do not miss out on the latest developments!

FEATURED SPEAKERS

Ian D Wilson worked in the pharmaceutical industry for 36 years, most recently as a senior Principal Scientist in the Dept. of Drug Metabolism and Pharmacokinetics at the AstraZeneca research site at Alderley Park in Cheshire, in the UK. In 2012 he moved to Imperial College (London) where he is Professor of Drug metabolism and Molecular Toxicology in the Dept of Surgery and cancer. His research is centred on metabolic phenotyping, drug metabolism, the microbiome and drug bioanalysis, with a particular emphasis on xenobiotic metabolism as a source of adverse drug reactions.

Pau Aceves joined Certara Strategic Consulting in February 2017. Pharmacist by training, and with previous work experience in diverse aspects of the Pharmacy practice—including Community, Clinical and Production Pharmacy—Pau focused his professional career path in the field of Quantitative Clinical Pharmacology (QCP) and PK/PD Modeling & Simulation, since 2006.

Pau Aceves holds a Master’s Degree in PK/PD Modeling & Simulation from the University of Manchester in the UK. His MSc project was on an Exploratory Quantitaitve Systems Pharmacology Model (QSP) of the Squalene Synthase Inhibitor Lapaquistat Acetate.

In addition to having worked on QCP-type studies (ie, food effect, bioavailability, DDIs), Pau also has a wide range of experience on other modalities, including: First-in-human (SAD/MAD), Proof-of-mechanism (PoM), Proof-of-concept (PoC), Positron Emission Tomography (PET), and complex combination (or umbrella-type) protocols; as well as experience interacting with regulatory agencies (FDA, EMEA) at various stages of drug development.

He has a total of 11 years of QCP experience in the design, analysis and reporting of studies in a wide range of therapeutic areas across all phases of drug development. Pau always enjoys devising innovative strategies to streamline and maximize the value of clinical development programmes by combining efficient clinical strategies with fit-for-purpose PK/PD analysis methods, eg, Population PK/PD, Physiologically-based Pharmacokinetic modeling, and Quantitative Systems Pharmacology approaches.

Dr. Robert A.B. van Waterschoot is currently a Group Head of DMPK/PD Project Leaders at the Roche Innovation Centers in Basel, Copenhagen and New York.

Prior to his career at Roche, he acquired experience in the DMPK departments of Merck (USA), Solvay Pharmaceuticals (the Netherlands) and Abbott/AbbVie (Germany).

Dr. Van Waterschoot has an MSc degree in Molecular Toxicology from the VU University Amsterdam and a PhD degree in Pharmacokinetics & Drug Toxicity from the Dutch Cancer Institute in Amsterdam. He has more then 20 peer-reviewed publications in the field of DMPK.

Dr Schulz-Utermoehl has over 19 years experience in the pharmaceutical industry, spanning early and late-stage discovery research and preclinical development. He has held senior roles at Merck, AstraZeneca and Shire and is currently the Director of DMPK & Physical Sciences at Sygnature Discovery. In parallel to his leadership role at Sygnature Discovery, he is also Vice President of Preclinical Development at Chronos Therapeutics and a Co-founder and NED of Belfry Therapeutics.

Dr Schulz-Utermoehl carried out 2 years of post-doctoral research at Novo Nordisk A/S, Denmark and holds a PhD in Biochemistry from Imperial College, a MSc in Toxicology from the Royal Postgraduate Medical School, University of London and a BSc (Hons) in Pharmacology/Physiology from the University of Leeds.

Andreas Reichel

VP, Head Research Pharmacokinetics, Bayer

Eric Blomme

Vice President Preclinical Safety, AbbVie

Filipe Lopes

DMPK Laboratory Head, Roche

After completing a PhD in Analytical Chemistry at King’s College London 2012, Filipe initiated his professional career at Novartis NIBR, in the UK where he helped setting-up a new mass spectrometry based lab to support enzymology studies within respiratory diseases. Decided to expand his skill set in DMPK, and in particular Drug Metablism, gained experience as a Biotransformation and Senior DMPK Scientist at Pharmaron and Evotec and in 2015 joined Roche pRED Basel as Laboratory Head in Drug Metabolism. Currently, Filipe is involved in projects that cover a wide variety of modalities (Small and Large molecules) across various therapeutic areas, including Oncology and Neurosciences.

Ian Wilson

Chair, Drug Metabolism and Molecular Toxicology, Imperial College

Ian D Wilson worked in the pharmaceutical industry for 36 years, most recently as a senior Principal Scientist in the Dept. of Drug Metabolism and Pharmacokinetics at the AstraZeneca research site at Alderley Park in Cheshire, in the UK. In 2012 he moved to Imperial College (London) where he is Professor of Drug metabolism and Molecular Toxicology in the Dept of Surgery and cancer. His research is centred on metabolic phenotyping, drug metabolism, the microbiome and drug bioanalysis, with a particular emphasis on xenobiotic metabolism as a source of adverse drug reactions.

Kunal Taskar

Senior Investigator & Associate Fellow, GSK

Laurent Salphati

Principal Scientist, Genentech, Inc.

Pau Aceves

Associate Director, Certara Strategic Counselling

Pau Aceves joined Certara Strategic Consulting in February 2017. Pharmacist by training, and with previous work experience in diverse aspects of the Pharmacy practice—including Community, Clinical and Production Pharmacy—Pau focused his professional career path in the field of Quantitative Clinical Pharmacology (QCP) and PK/PD Modeling & Simulation, since 2006.

Pau Aceves holds a Master’s Degree in PK/PD Modeling & Simulation from the University of Manchester in the UK. His MSc project was on an Exploratory Quantitaitve Systems Pharmacology Model (QSP) of the Squalene Synthase Inhibitor Lapaquistat Acetate.

In addition to having worked on QCP-type studies (ie, food effect, bioavailability, DDIs), Pau also has a wide range of experience on other modalities, including: First-in-human (SAD/MAD), Proof-of-mechanism (PoM), Proof-of-concept (PoC), Positron Emission Tomography (PET), and complex combination (or umbrella-type) protocols; as well as experience interacting with regulatory agencies (FDA, EMEA) at various stages of drug development.

He has a total of 11 years of QCP experience in the design, analysis and reporting of studies in a wide range of therapeutic areas across all phases of drug development. Pau always enjoys devising innovative strategies to streamline and maximize the value of clinical development programmes by combining efficient clinical strategies with fit-for-purpose PK/PD analysis methods, eg, Population PK/PD, Physiologically-based Pharmacokinetic modeling, and Quantitative Systems Pharmacology approaches.

Peter Littlewood

Robert van Waterschoot

Dr. Robert A.B. van Waterschoot is currently a Group Head of DMPK/PD Project Leaders at the Roche Innovation Centers in Basel, Copenhagen and New York.

Prior to his career at Roche, he acquired experience in the DMPK departments of Merck (USA), Solvay Pharmaceuticals (the Netherlands) and Abbott/AbbVie (Germany).

Dr. Van Waterschoot has an MSc degree in Molecular Toxicology from the VU University Amsterdam and a PhD degree in Pharmacokinetics & Drug Toxicity from the Dutch Cancer Institute in Amsterdam. He has more then 20 peer-reviewed publications in the field of DMPK.

Timothy Schulz-Utermoehl

Director of DMPK, Sygnature Discovery Ltd

Dr Schulz-Utermoehl has over 19 years experience in the pharmaceutical industry, spanning early and late-stage discovery research and preclinical development. He has held senior roles at Merck, AstraZeneca and Shire and is currently the Director of DMPK & Physical Sciences at Sygnature Discovery. In parallel to his leadership role at Sygnature Discovery, he is also Vice President of Preclinical Development at Chronos Therapeutics and a Co-founder and NED of Belfry Therapeutics.

Dr Schulz-Utermoehl carried out 2 years of post-doctoral research at Novo Nordisk A/S, Denmark and holds a PhD in Biochemistry from Imperial College, a MSc in Toxicology from the Royal Postgraduate Medical School, University of London and a BSc (Hons) in Pharmacology/Physiology from the University of Leeds.

VENUE

Holiday Inn Kensington Forum

97 Cromwell Road , London, United Kingdom

Holiday Inn Kensington Forum is perfectly situated in one of London’s most luxurious and beautiful areas within South Kensington.

The hotel is just 2 minutes walk from Gloucester Road tube station for convenient travel to Hyde Park, London Eye, Tower Bridge plus more of London’s top attractions. There are also easy and direct links to some major transport hubs including Victoria, Kings Cross St Pancras, Paddington and Heathrow.

This distinctive hotel in south London has so much to offer to make all guests really feel at home. The latest Holiday Inn relaunch is not just about the new look and feel for the hotel but to offer guests more benefits during their stay including a pillow menu for extra comfort during their sleep and a curved shower rail for more spacious feel.

In addition to our 906 rooms, all business guests can take advantage of our meeting and conference facilities including High Speed Internet Access and unlimited Starbucks coffee at The Academy. Our hotel’s professional event planners are on board to help take the hard work and stress away from planning your next event.

So whether you in London on business or pleasure, make the Holiday Inn London Kensington Forum your first choice of hotel and book your accommodation for our lowest internet rate guarantee.

SAVE TO

Holiday Inn Kensington Forum

97 Cromwell Road
London SW7 4DN
United Kingdom

Holiday Inn Kensington Forum is perfectly situated in one of London’s most luxurious and beautiful areas within South Kensington.

The hotel is just 2 minutes walk from Gloucester Road tube station for convenient travel to Hyde Park, London Eye, Tower Bridge plus more of London’s top attractions. There are also easy and direct links to some major transport hubs including Victoria, Kings Cross St Pancras, Paddington and Heathrow.

This distinctive hotel in south London has so much to offer to make all guests really feel at home. The latest Holiday Inn relaunch is not just about the new look and feel for the hotel but to offer guests more benefits during their stay including a pillow menu for extra comfort during their sleep and a curved shower rail for more spacious feel.

In addition to our 906 rooms, all business guests can take advantage of our meeting and conference facilities including High Speed Internet Access and unlimited Starbucks coffee at The Academy. Our hotel’s professional event planners are on board to help take the hard work and stress away from planning your next event.

So whether you in London on business or pleasure, make the Holiday Inn London Kensington Forum your first choice of hotel and book your accommodation for our lowest internet rate guarantee.

Cookie Policy

From May 2011 a new privacy law came into effect across the EU. The law requires
that websites ask visitors for consent to use most web cookies. We use cookies to
ensure you get the best experience on our website –Tick here to accept cookie use
Details of our cookie use may be found here.

WHAT IS CPD?

CPD stands for Continuing Professional Development’. It is essentially a philosophy,
which maintains that in order to be effective, learning should be organised and
structured. The most common definition is:

‘A commitment to structured skills and knowledge enhancement for Personal or Professional
competence’

CPD is a common requirement of individual membership with professional bodies and
Institutes. Increasingly, employers also expect their staff to undertake regular
CPD activities.

Undertaken over a period of time, CPD ensures that educational qualifications do
not become obsolete, and allows for best practice and professional standards to
be upheld.

CPD can be undertaken through a variety of learning activities including instructor
led training courses, seminars and conferences, e:learning modules or structured
reading.

CPD AND PROFESSIONAL INSTITUTES

There are approximately 470 institutes in the UK across all industry sectors, with
a collective membership of circa 4 million professionals, and they all expect their
members to undertake CPD.

For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked
to a licence to practice, for others it’s obligatory. By ensuring that their members
undertake CPD, the professional bodies seek to ensure that professional standards,
legislative awareness and ethical practices are maintained.

CPD Schemes often run over the period of a year and the institutes generally provide
online tools for their members to record and reflect on their CPD activities.

TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

Professional bodies and Institutes CPD schemes are either structured as ‘Input’
or ‘Output’ based.

‘Input’ based schemes list a precise number of CPD hours that individuals must achieve
within a given time period. These schemes can also use different ‘currencies’ such
as points, merits, units or credits, where an individual must accumulate the number
required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of
learning.

‘Output’ based schemes are learner centred. They require individuals to set learning
goals that align to professional competencies, or personal development objectives.
These schemes also list different ways to achieve the learning goals e.g. training
courses, seminars or e:learning, which enables an individual to complete their CPD
through their preferred mode of learning.

As a formal provider of CPD certified activities, SMI Group can provide an indication
of the learning benefit gained and the typical completion. However, it is ultimately
the responsibility of the delegate to evaluate their learning, and record it correctly
in line with their professional body’s or employers requirements.

GLOBAL CPD

Increasingly, international and emerging markets are ‘professionalising’ their workforces
and looking to the UK to benchmark educational standards. The undertaking of CPD
is now increasingly expected of any individual employed within today’s global marketplace.

CPD Certificates

We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk